{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:06:34Z","timestamp":1790262394624,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":42,"publisher":"Springer New York","isbn-type":[{"value":"9781461450368","type":"print"},{"value":"9781461450375","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-1-4614-5037-5_7","type":"book-chapter","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T14:17:16Z","timestamp":1353075436000},"page":"145-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Helicase\u2013Primase Complex as a Target for Effective Herpesvirus Antivirals"],"prefix":"10.1007","author":[{"given":"Hugh J.","family":"Field","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Mickleburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"7_CR1","first-page":"58","volume":"31","author":"HJ Field","year":"2004","unstructured":"Field HJ, De Clercq E. Antiviral drugs: a short history of their discovery and development. Microbiol Today. 2004;31:58\u201361.","journal-title":"Microbiol Today."},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","volume":"147","author":"E Clercq De","year":"2006","unstructured":"De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006;147:1\u201311.","journal-title":"Br J Pharmacol"},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/095632020301400405","volume":"14","author":"JG Harmenberg","year":"2003","unstructured":"Harmenberg JG, Awan AR, Alenius S, Stahle L, Erlandsson AC, Lekare G, et al. ME-609: a treatment for recurrent herpes simplex virus infections. Antivir Chem Chemother. 2003;14:205\u201315.","journal-title":"Antivir Chem Chemother"},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1073\/pnas.86.7.2186","volume":"86","author":"JJ Crute","year":"1989","unstructured":"Crute JJ, Tsurumi T, Zhu L, Weller SK, Olivo PD, Challberg MD, et al. Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products. Proc Natl Acad Sci USA. 1989;86:2186\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.1128\/JVI.72.9.6979-6987.1998","volume":"72","author":"FC Spector","year":"1998","unstructured":"Spector FC, Liang L, Giordano H, Sivaraja M, Peterson MG. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol. 1998;72:6979\u201387.","journal-title":"J Virol"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1128\/JVI.66.1.469-479.1992","volume":"66","author":"L Zhu","year":"1992","unstructured":"Zhu L, Weller SK. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function. J Virol. 1992;66:469\u201379.","journal-title":"J Virol"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nm0402-386","volume":"8","author":"JJ Crute","year":"2002","unstructured":"Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher A-M, Bolger G, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med. 2002;8:386\u201391.","journal-title":"Nat Med"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1128\/AAC.47.6.1798-1804.2003","volume":"47","author":"J Duan","year":"2003","unstructured":"Duan J, Liuzzi M, Paris W, Liard F, Browne A, Dansereau N, et al. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother. 2003;47:1798\u2013804.","journal-title":"Antimicrob Agents Chemother"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med. 2002;8:392\u20138.","journal-title":"Nat Med"},{"key":"7_CR10","first-page":"46","volume":"10","author":"G Kleymann","year":"2003","unstructured":"Kleymann G. New antiviral drugs against herpesviruses. Herpes. 2003;10:46\u201352.","journal-title":"Herpes"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","volume":"4","author":"UAK Betz","year":"2002","unstructured":"Betz UAK, Fischer R, Kleymann G, Hendrix M, R\u00fcbsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY57-1293. Antimicrob Agents Chemother. 2002;4:1766\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0022-510X(83)90061-8","volume":"60","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Field HJ. The distribution of herpes simplex type 1 antigen in mouse central nervous system after different routes of inoculation. J Neurol Sci. 1983;60:181\u201395.","journal-title":"J Neurol Sci"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/095632020701800104","volume":"18","author":"J Baumeister","year":"2007","unstructured":"Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother. 2007;18:35\u201348.","journal-title":"Antivir Chem Chemother"},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF00509241","volume":"277","author":"J Harmenberg","year":"1985","unstructured":"Harmenberg J, Abele G, Malm M. Deoxythymidine pools in animal and human skin with reference to antiviral drugs. Arch Dermatol Res. 1985;277:402\u20133.","journal-title":"Arch Dermatol Res"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0166-3542(85)90033-6","volume":"5","author":"J Harmenberg","year":"1985","unstructured":"Harmenberg J, Abele G, Wahren B. Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells. Antiviral Res. 1985;5:75\u201381.","journal-title":"Antiviral Res."},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","volume":"75","author":"S Biswas","year":"2007","unstructured":"Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1. Antiviral Res. 2007;75:30\u20135.","journal-title":"Antiviral Res"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2217\/fvl.11.28","volume":"6","author":"A Birkmann","year":"2011","unstructured":"Birkmann A, Hewlett G, Rubsamen-Schaeff H, Zimmermann H. Helicase primase inhibitors as the potential next gerneration of highly active drugs against herpes simplex viruses. Future Virol. 2011;6:1199\u2013209.","journal-title":"Future Virol."},{"key":"7_CR18","unstructured":"Birkman A, Kropeit D, Biswas S, Paulsen D, Sukla S, Field HJ. PK\/PD evaluation of AIC316, a novel herpes simplex virus inhibitor currently in clinical development. Presented at Antivirals congress, Amsterdam, The Netherlands; 7\u20139 Nov 2010."},{"key":"7_CR19","unstructured":"Wald A, Stoellben S, Tyring S, Warren T, Johnston C, Huang M-L, et al. Impact of AIC316, a novel antiviral helicase-primase inhibitor, on genital HSV shedding: randomized, double-blind, placebo-controlled trial. Presented at 19th Biennial conference of the International Society of Sexually Transmitted Diseases Research (ISSTDR) Quebec City, QC, Canada; 10\u201313 July 2011."},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokota T, et al. ASP2151, a novel helicase\u2013primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65:1733\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokata T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65:1733\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.3390\/molecules16097210","volume":"16","author":"K Katsumata","year":"2011","unstructured":"Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes. Molecules. 2011;16:7210\u201323.","journal-title":"Molecules"},{"key":"7_CR23","unstructured":"ClinicalTrials.gov. Dose-finding study of ASP2151 in subjects with herpes zoster. \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00487682\n\n; \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00487682\n\n."},{"key":"7_CR24","unstructured":"ClinicalTrials.gov. A study with ASP2151 in subjects with recurrent episodes of genital herpes. \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00486200\n\n; \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00486200\n\n\n."},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1386-6532(00)00169-4","volume":"21","author":"HJ Field","year":"2001","unstructured":"Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol. 2001;21:261\u20139.","journal-title":"J Clin Virol"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","volume":"16","author":"TH Bacon","year":"2003","unstructured":"Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114\u201328.","journal-title":"Clin Microbiol Rev"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/AAC.22.1.71","volume":"22","author":"DS Parris","year":"1982","unstructured":"Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982;22:71\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"7_CR28","first-page":"88","volume":"5","author":"C Gilbert","year":"2002","unstructured":"Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Antiviral Res. 2002;5:88\u2013114.","journal-title":"Antiviral Res."},{"key":"7_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1128\/AAC.42.4.868","volume":"42","author":"J Christophers","year":"1998","unstructured":"Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother. 1998;42:868\u201372.","journal-title":"Antimicrob Agents Chemother."},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/20.3.389","volume":"20","author":"J Christophers","year":"1987","unstructured":"Christophers J, Sutton RN. Characterization of acyclovir-resistant and sensitive clinical isolates of herpes simplex virus isolates from an immunocompromised patient. J Antimicrob Chemother. 1987;20:389\u201398.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.antiviral.2004.02.007","volume":"64","author":"M Liuzzi","year":"2004","unstructured":"Liuzzi M, Kibler P, Bousquet C, Harji F, Bolger G, Garneau M, et al. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res. 2004;64:161\u201370.","journal-title":"Antiviral Res"},{"key":"7_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","volume":"14","author":"HJ Field","year":"2011","unstructured":"Field HJ, Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist Updat. 2011;14:45\u201351.","journal-title":"Drug Resist Updat"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/9783527635955.ch6","volume-title":"Antiviral drug strategies","author":"S Biswas","year":"2011","unstructured":"Biswas S, Field HJ. Helicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella-zoster virus. In: De Clercq E, editor. Antiviral drug strategies. Weinheim: Wiley; 2011. p. 129\u201345."},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/095632020701800102","volume":"18","author":"S Biswas","year":"2007","unstructured":"Biswas S, Swift M, Field HJ. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir Chem Chemother. 2007;18:13\u201323.","journal-title":"Antivir Chem Chemother"},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jac\/dkm182","volume":"60","author":"S Biswas","year":"2007","unstructured":"Biswas S, Smith C, Field HJ. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1. J Antimicrob Chemother. 2007;60:274\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jac\/dkq135","volume":"65","author":"S Sukla","year":"2010","unstructured":"Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field H. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. J Antimicrob Chemother. 2010;65:1347\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.antiviral.2010.04.008","volume":"87","author":"S Sukla","year":"2010","unstructured":"Sukla S, Biswas S, Birkmann A, Lischka P, Ruebsamen-Schaeff H, Zimmermann H, et al. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Res. 2010;87:67\u201373.","journal-title":"Antiviral Res."},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00705-007-0964-7","volume":"152","author":"S Biswas","year":"2007","unstructured":"Biswas S, Jennens L, Field HJ. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch Virol. 2007;152:1489\u2013500.","journal-title":"Arch Virol"},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.antiviral.2008.04.005","volume":"80","author":"S Biswas","year":"2008","unstructured":"Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 2008;80:81\u20135.","journal-title":"Antiviral Res"},{"key":"7_CR40","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jac\/dkn057","volume":"61","author":"S Biswas","year":"2008","unstructured":"Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre-Hern\u00e1ndez J, et al. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J Antimicrob Chemother. 2008;61:1044\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"7_CR41","unstructured":"Field HJ, Mickelburgh I, Huang M-L, Tiley L, Wald A, Ruebsamen-Schaeff H, et al. Sensitivity of Clinical isolates to helicase primase inhibitors and no detection of resistance mutations above background frequency. In: Twenty fifth international conference on antiviral research, Sapporo, Japan; 2012, Abstract 46."},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1099\/vir.0.011221-0","volume":"90","author":"S Biswas","year":"2009","unstructured":"Biswas S, Miguel RN, Sukla S, Field HJ. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J Gen Virol. 2009;90:1937\u201342.","journal-title":"J Gen Virol"}],"container-title":["Advances in Experimental Medicine and Biology","DNA Helicases and DNA Motor Proteins"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-5037-5_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T05:12:24Z","timestamp":1583471544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4614-5037-5_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"ISBN":["9781461450368","9781461450375"],"references-count":42,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-5037-5_7","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,29]]},"assertion":[{"value":"29 October 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}